The move was made following the termination of collaboration between both the companies.
AbGn-168H, a humanized monoclonal antibody against CD-162 preferentially induces apoptosis of late-stage activated T-cells and is under development to treat psoriasis and other immunological diseases.
AbGenomics intends to carry on with the development of AbGn-168H in psoriasis as well as in other immune and inflammatory disease indications and hence will seek a new partner.
AbGenomics founder and CEO Rong- Hwa Lin said the company had a good collaboration agreement with Boehringer Ingelheim since 2005.
"While we will continue to develop AbGn-168H for psoriasis, regaining the global rights will also permit us to consider other indications that will take advantage of the full therapeutic potential of this drug," Hwa Lin added.